文献速递癫痫

司美格鲁肽与成人起病癫痫风险:目标试验模拟

Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation.
PubMed 文献 · Neurology · 2026-06-17

该研究利用All of Us研究计划模拟目标试验,比较2型糖尿病患者启动司美格鲁肽与其他降糖药或SGLT2i后成人起病癫痫的发生风险。结果显示司美格鲁肽与较低的癫痫风险相关,且该关联独立于血糖和体重效应。

要点

  • 司美格鲁肽较其他降糖药与成人起病癫痫风险降低相关(加权HR 0.44)。
  • 司美格鲁肽较SGLT2i也与癫痫风险降低相关(加权HR 0.48)。
  • 中介分析显示HbA1c和BMI的介导比例很小。

核心结论

  • 在2型糖尿病成人中,启动司美格鲁肽与较低的成人起病癫痫风险相关,且独立于血糖和体重效应。

研究设计与样本

  • 基于All of Us研究计划,模拟2018年1月至2023年10月的新使用者、活性对照目标试验。
  • 司美格鲁肽(n=2586) vs 其他降糖药(n=7627)队列共10213人。
  • 司美格鲁肽(n=2814) vs SGLT2i(n=5791)队列共8605人。

主要发现

  • 司美格鲁肽 vs 其他降糖药:加权HR 0.44(95%CI 0.25-0.79),4年风险差-1.78%(95%CI -2.58至-0.98)。
  • 司美格鲁肽 vs SGLT2i:加权HR 0.48(95%CI 0.27-0.85),4年风险差-1.46%(95%CI -2.41至-0.51)。
  • TMLE估计每1000人风险差:vs其他降糖药-14.20(95%CI -18.33至-10.07),vs SGLT2i -7.62(95%CI -11.65至-3.60),NNT分别为70和131。
  • 中介分析:HbA1c介导比例vs其他降糖药2.4%、vs SGLT2i 6.5%;BMI介导比例0%和0.7%。

临床怎么用

  • 对于2型糖尿病成人,司美格鲁肽可能有助于降低成人起病癫痫风险,但需结合个体情况权衡。

局限性

  • 存在残余混杂、事件数少和随访时间较短,限制因果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Adult-onset seizure reflects the burden of acquired brain insults, but established disease-modifying preventive strategies are limited. We evaluated whether semaglutide initiation is associated with a lower incidence of adult-onset seizure compared with sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other glucose-lowering drugs (GLDs) in adults with type 2 diabetes. METHODS: Using the All of Us Research Program, we emulated a population-based target trial in new-user, active-comparator cohorts from January 2018 to October 2023. We compared semaglutide vs other GLDs and semaglutide vs SGLT2i. Incident epilepsy or seizure was identified from diagnostic codes. Effects were estimated using inverse probability of treatment weighting with weighted Cox models and targeted maximum likelihood estimation (TMLE). Subgroup and sensitivity analyses with multiple outcome definitions and analytic approaches were conducted to assess the robustness of findings. We evaluated mediation through hemoglobin A1c (HbA1c) and body mass index (BMI) using the longitudinal Vansteelandt framework. RESULTS: We analyzed 10,213 patients in the semaglutide (n = 2,586, mean age, 60.1 years; 56.8% female) vs other GLDs cohort (n = 7,627, mean age, 63.7 years; 54.2% female) and 8,605 patients in the semaglutide (n = 2,814, mean age, 60.5 years; 66.2% female) vs SGLT2i cohort (n = 5,791, mean age, 64.4 years; 47.3% female). Semaglutide was associated with a lower risk of adult-onset seizure compared with other GLDs (weighted HR 0.44 [95% CI 0.25-0.79]; 4-year risk difference -1.78% [95% CI -2.58 to -0.98]) and SGLT2i (weighted HR 0.48 [95% CI 0.27-0.85]; 4-year risk difference -1.46% [95% CI -2.41 to -0.51]). TMLE estimated risk differences per 1,000 persons of -14.20 (95% CI -18.33 to -10.07) vs other GLDs and -7.62 (95% CI -11.65 to -3.60) vs SGLT2i, corresponding to numbers needed to treat of 70 and 131, respectively. Mediation was minimal for HbA1c (2.4% vs other GLDs; 6.5% vs SGLT2i) and BMI (0% vs other GLDs; 0.7% vs SGLT2i). DISCUSSION: Semaglutide initiation was associated with a lower risk of adult-onset seizure compared with SGLT2i and other GLDs in patients with type 2 diabetes, independent of glycemic and weight effects. Residual confounding, low event counts, and shorter follow-up limit causal interpretation. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that semaglutide use was associated with a lower risk of adult-onset seizures compared with other GLDs and SGLT2i.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Eun Y, Bong S, Koh HY, et al. Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation. Neurology. 2026. PMID: 42308439. doi:10.1212/WNL.0000000000218174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。